CVS Health reaches FTC settlement over pharmacy benefit practices
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/2/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- DataMeds AI's Corexa Pharmacy tops $1M in monthly revenue
- Equities rebound to close higher as surging Treasury yields recede
- onsemi cuts Synaptics deal price to $5.7B after rival bid
- Twilio, Vylor set to join S&P 500 as index reshuffles members
- Wells Fargo names 13 stocks as overweight tactical ideas
CVS Caremark Announces Agreement with FTC To Further Advance Industry-Leading Approaches to Transparency and Affordability
July 14, 2026 3:06 PM EDTWOONSOCKET, R.I., July 14, 2026 /PRNewswire/ -- CVS Caremark today announced a global settlement with the Federal Trade Commission (FTC) which further advances the company's leadership in delivering greater affordability for prescription drugs. The settlement resolves all outstanding FTC litigation and investigations related to CVS Health® (NYSE: CVS) including its pharmacy benefits management and affiliated pharmacy businesses involving rebate, pharmacy network contracting, and vertical... More
